Sygnature Discovery (Formerly known as Sygnature Chemical Services)
BioCity, Pennyfoot Street
11 articles with Sygnature Discovery (Formerly known as Sygnature Chemical Services)
Sygnature Discovery has added in-house high-throughput screening (HTS) to its range of drug discovery services.
The space occupied by a drug molecule in three dimensions, and how it fits into the target, is an important consideration when designing a new compound that might become a drug.
Sygnature Discovery, the leading independent drug discovery and pre-clinical services company, has announced its US office has moved.
Dr Moore is an internationally recognised drug discovery and development specialist who has spent nearly 40 years working in the field of in vivo pharmacology.
Figure of FragMaps for a given protein structure.
Sygnature Discovery starts 2019 with two senior appointments: Dr Allan Jordan and Ms Louisa Jordison
Sygnature Discovery, the leading independent integrated drug discovery and pre-clinical services provider, have made two key appointments. Dr Allan Jordan and Ms Louisa Jordison have joined the organisation as they continue their strong growth trajectory in the drug research market.
CellCentric Ltd. Selects Sygnature Discovery (Formerly known as Sygnature Chemical Services) for Epigenetic Prostate Cancer Program
Sygnature Chemical Services Announces Significant Increase in Medicinal Chemistry Team with Recruitment of AstraZeneca PLC and Merck & Co., Inc. Scientists
University of Leicester Selects Sygnature Chemical Services To Support Wellcome Trust-Funded Pneumococcal Diseases Project
Sygnature Chemical Services Strengthens Scientific Team: Dr Michael Knaggs Appointed As Head Of Computational Chemistry